These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 18368061)

  • 1. Long-term sequelae of postnatal surfactant and corticosteroid therapies for BPD.
    Short EJ; Kirchner HL; Asaad GR; Fulton S; Lewis B; Eisengart S; Baley J; Kercsmar C; Min MO; Singer LT
    J Perinatol; 2008 Jul; 28(7):498-504. PubMed ID: 18368061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developmental sequelae in preterm infants having a diagnosis of bronchopulmonary dysplasia: analysis using a severity-based classification system.
    Short EJ; Kirchner HL; Asaad GR; Fulton SE; Lewis BA; Klein N; Eisengart S; Baley J; Kercsmar C; Min MO; Singer LT
    Arch Pediatr Adolesc Med; 2007 Nov; 161(11):1082-7. PubMed ID: 17984411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in the use of postnatal steroids for bronchopulmonary dysplasia in 3 large neonatal networks.
    Walsh MC; Yao Q; Horbar JD; Carpenter JH; Lee SK; Ohlsson A
    Pediatrics; 2006 Nov; 118(5):e1328-35. PubMed ID: 17079534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of surfactant and antenatal corticosteroid treatment on the pulmonary pathology of preterm infants with respiratory distress syndrome.
    Teksam O; Kale G
    Pathol Res Pract; 2009; 205(1):35-41. PubMed ID: 18951732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bronchopulmonary dysplasia - prevalence, severity and predictive factors in a national cohort of extremely premature infants.
    Farstad T; Bratlid D; Medbø S; Markestad T;
    Acta Paediatr; 2011 Jan; 100(1):53-8. PubMed ID: 20653607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of bronchopulmonary dysplasia after participation in the Breathsavers Group of the Vermont Oxford Network Neonatal Intensive Care Quality Improvement Collaborative.
    Payne NR; LaCorte M; Karna P; Chen S; Finkelstein M; Goldsmith JP; Carpenter JH;
    Pediatrics; 2006 Nov; 118 Suppl 2():S73-7. PubMed ID: 17079626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug therapies in bronchopulmonary dysplasia: debunking the myths.
    Tin W; Wiswell TE
    Semin Fetal Neonatal Med; 2009 Dec; 14(6):383-90. PubMed ID: 19747890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bronchopulmonary dysplasia.
    Deakins KM
    Respir Care; 2009 Sep; 54(9):1252-62. PubMed ID: 19712501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time-related changes in steroid use and bronchopulmonary dysplasia in preterm infants.
    Yoder BA; Harrison M; Clark RH
    Pediatrics; 2009 Aug; 124(2):673-9. PubMed ID: 19620192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surfactant, steroids and non-invasive ventilation in the prevention of BPD.
    Dumpa V; Bhandari V
    Semin Perinatol; 2018 Nov; 42(7):444-452. PubMed ID: 30343941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhalation or instillation of steroids for the prevention of bronchopulmonary dysplasia.
    Bassler D
    Neonatology; 2015; 107(4):358-9. PubMed ID: 26044104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dexamethasone therapy in preterm infants developing bronchopulmonary dysplasia: effect on pulmonary surfactant disaturated-phosphatidylcholine kinetics.
    Cogo PE; Simonato M; Mariatoffolo G; Stefanutti G; Chierici M; Cobelli C; Ori C; Carnielli VP
    Pediatr Res; 2008 Apr; 63(4):433-7. PubMed ID: 18356753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of inhaled glucocorticosteroids and recovery from adrenal suppression after systemic steroid use in a VLBW premature infant with BPD: case report and literature discussion.
    Karinski DA; Balkundi D; Rubin LP; Padbury JF
    Neonatal Netw; 2000 Dec; 19(8):27-32. PubMed ID: 11949271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postnatal corticosteroids for preterm infants--do what we say, not what we do.
    Jobe AH
    N Engl J Med; 2004 Mar; 350(13):1349-51. PubMed ID: 15044647
    [No Abstract]   [Full Text] [Related]  

  • 15. Intratracheal budesonide mixed with surfactant to increase survival free of bronchopulmonary dysplasia in extremely preterm infants: study protocol for the international, multicenter, randomized PLUSS trial.
    Manley BJ; Kamlin COF; Donath S; Huang L; Birch P; Cheong JLY; Dargaville PA; Dawson JA; Doyle LW; Jacobs SE; Wilson R; Davis PG; McKinlay CJD
    Trials; 2023 May; 24(1):320. PubMed ID: 37161488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison outcomes of surfactant therapy in respiratory distress syndrome in two periods.
    Chotigeat U; Promwong N; Kanjanapattanakul W; Khorana M; Sangtawesin V; Horpaopan S
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S109-14. PubMed ID: 19253505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot randomized, controlled trial of later treatment with a peptide-containing, synthetic surfactant for the prevention of bronchopulmonary dysplasia.
    Laughon M; Bose C; Moya F; Aschner J; Donn SM; Morabito C; Cummings JJ; Segal R; Guardia C; Liu G;
    Pediatrics; 2009 Jan; 123(1):89-96. PubMed ID: 19117865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Health status at the age of 5-7 years of preterm infants with and without bronchopulmonary dysplasia].
    Kwinta P; Tomasik T; Klimek M; Cichocka-Jarosz E; Lis G; Pietrzyk JJ
    Przegl Lek; 2009; 66(1-2):21-6. PubMed ID: 19485251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pitfalls, problems, and progress in bronchopulmonary dysplasia.
    Bhandari A; Bhandari V
    Pediatrics; 2009 Jun; 123(6):1562-73. PubMed ID: 19482769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surfactant replacement therapy in the neonate: beyond respiratory distress syndrome.
    Donn SM; Dalton J
    Respir Care; 2009 Sep; 54(9):1203-8. PubMed ID: 19712497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.